A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures
收藏DataCite Commons2026-03-18 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00000248/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 1200 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).
提供机构：
Vivli
创建时间：
2018-10-27
